title: Re: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762.
authors.forename: H J
authors.initials: HJ
authors.lastname: deVoogt
authors.forename: M
authors.initials: M
authors.lastname: Pavone-Macaluso
authors.forename: R
authors.initials: R
authors.lastname: Sylvester
authors.forename: F H
authors.initials: FH
authors.lastname: Schröder
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D003534:Cyproterone / Q000009:adverse effects / Q000031:analogs & derivatives; D017373:Cyproterone Acetate; D004054:Diethylstilbestrol / Q000009:adverse effects; D004961:Estramustine / Q000009:adverse effects; D006321:Heart / Q000187:drug effects*; D006801:Humans; D008297:Male; D008525:Medroxyprogesterone / Q000009:adverse effects / Q000031:analogs & derivatives; D017258:Medroxyprogesterone Acetate; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D004961:Estramustine; D017373:Cyproterone Acetate; D004054:Diethylstilbestrol; D017258:Medroxyprogesterone Acetate; D003534:Cyproterone; D008525:Medroxyprogesterone